

Considerations for Medication for Addiction Treatment in Patients with HIV

Patient name: _____

Current HAART regimen: _____

Most recent CD4+ count: _____ Date: _____

Most recent HIV viral load result: _____ Date: _____

HIV provider contact information: _____

Points for discussion:

Treatment for opioid use disorder will not interfere with HIV management

Treatment selection will be determined by clinical opioid need

If naltrexone therapy is planned, key discussion point:

- No interaction with antiretrovirals

If buprenorphine/naloxone treatment is planned, key discussion points:

- Buprenorphine/naloxone has a more benign drug interaction profile than methadone
- Protease inhibitors may increase buprenorphine/naloxone levels; not clinically significant except for:
 - Increases in buprenorphine/naloxone levels with atazanavir and atazanavir/ritonavir associated with sedation and cognitive impairment; may require decreased buprenorphine/naloxone dose for symptoms to disappear
 - Advise patient of possible side effects
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
 - May decrease buprenorphine/naloxone levels and cause withdrawal symptoms; may require need for increased buprenorphine/naloxone dose
 - Advise patient of possible side effects

Notes from patient discussion: _____

CONSIDER SCANNING THIS DOCUMENT INTO THE PATIENT RECORD.
MORE INFORMATION IS AVAILABLE IN THE OBAT POLICY AND PROCEDURE MANUAL